P. A-M

Check out this new #review! 👇 It highlights iPSC-derived #NKCells as a promising, genetically engineerable off-the-shelf #immunotherapy platform, while emphasizing that their clinical success depends on overcoming manufacturing, persistence, and functional maturation challenges. 🔗 bit.ly/4u4Jhwq

Gene Editing at Scale: Clinic Seeks Generalizable Therapies End-to-end pipelines and regulatory advances aim to expand #geneediting to broad patient populations @idtdna, @DanaherCorp, @elevatebio, @MassGeneralNews, @AuroraTher, and @MaxCyte_info #CRISPR hubs.li/Q04jlLTq0

Make plans to hear Shinya Yamanaka, the stem cell biologist best known for discovering iPSCs, discuss applications for iPSCs and where we are heading. He will present at both #ISSCR2026 and at ISSCR's iPSC 20th Anniversary Symposium in Kyoto this October. nature.com/articles/d4157…

🆕🧬 New in @GeneTherapy_SN! Researchers with Dr. Nirjal Bhattarai characterized soluble factors secreted by activated CAR-T cells derived from human peripheral blood and assessed their role in bystander #MyeloidCell activation. go.nature.com/4dAsTil

New work from the lab of Dr. Micah Drummond (@drummond_lab) at @uofunuip shows that aged #MuscleRecovery after disuse is impaired by the accumulation of senescent interstitial cells that drive inflammation and fibrosis. 🔓 Read the @ScienceAdvances study: bit.ly/3PJwYaW

Clinical data released this week by ARM member Eli Lilly and Company show that its gene therapy, which uses a base editor, lowered LDL-C by 62% in patients enrolled in its Phase 1b Heart-2 clinical trial. investor.lilly.com/news-releases/… 1/2

@RyanLeeMiniMax @ToNYD2WiLD @DataLearnerAI What size can we expect? Will it still fit in a M3 Ultra?

@ToNYD2WiLD @DataLearnerAI API first, and open weights when the weight is ready

Recently, we took time to consolidate all of the work behind M2 and published it here: our M2 paper on arXiv It’s been just over six months since we first open-sourced M2 on December 23 last year. During that time, a number of our ideas and systems have been broadly adopted by the open-source community — including CISPO, Forge RL System, Self-Evolution. Over the past six months, we’ve felt incredible enthusiasm from the open-source community. Nearly every model release reached the #1 spot on the Hugging Face leaderboard. Now it’s time for a new chapter. We’re getting ready for M3. MSA paper is on the road. arxiv.org/abs/2605.26494

Parabilis Files for IPO, a Day After Signing Up-to-$2.3B Regeneron Collaboration #ParabilisMedicines, developer of drugs and #ADCs for undruggable protein targets using stabilized helical peptides or Helicons, has filed for an IPO #GENEdge #industrynews hubs.li/Q04hVXM70

Through in vivo comparisons of synergistic armor combinations, Dr. Yvonne Chen and co-authors show that T cells expressing a CAR plus IL-12 and the decoy-resistant form of IL-18 show efficacy against antigen-heterogeneous #glioma in immunocompetent mice. bit.ly/4dK0wgr

Human and experimental atherosclerosis share core #mesenchymal cell phenotypes, but several distinct subtypes differ in presence or abundance. 📚 Check out their cross-species analysis: 🆕 bit.ly/4x7xqAG

New work from the lab of Dr. Hua Cai at @dgsomucla suggests a novel and paradigm-shifting concept that endothelial NOX1 drives systematic metabolic phenotypes, via impairment in skeletal muscle mitochondrial dysfunction with novel genetic signatures. Read the @CircRes study: bit.ly/4uABrMg

Perspective @sigtrans_sttt The in vivo revolution in CAR-T therapy medicinal products: challenges and regulatory prospects nature.com/articles/s4139…

GRAIL's Galleri 'multi-cancer early detection' (MCED) test has 60%+ sensitivity in Stage I/II pancreatic cancer, per the CCGA study. It also has the potential of detecting ~50 other cancer types at early stage. The goal: "Detect cancer early, when it can be cured." @GRAILBio @GalleriTest #DetectCancerEarly #MCED

Biomanufacturing Could Reshape Organ Transplantation Biofabrication and biomanufacturing advances aim to transform organ transplantation from scarcity to a scalable supply #BoyangWang #ImmortalDragons #GENbioprocessing #organtransplant #biomanufacturing hubs.li/Q04hGf8x0

The authors at @NCState investigated myocardial dECM-based fibrous scaffolds for iPSC-derived cardiomyocyte use Coaxially electrospun nanofibers comprising a polyurethane core and a blend of polycaprolactone and myocardial dECM as the sheath were optimized. 👉 bit.ly/4wYDhbs

Researchers discovered that SREBP1 drives heart failure progression by directly activating NHE3, disrupting sodium and calcium handling in #cardiomyocytes and impairing cardiac contraction. 🔓 #OpenAccess 🔖 bit.ly/3RFuScx

📢 New in @SciReports! Researchers led by Dr. Raghavan Chinnadurai at @mercersom have shown that AMD3100 alters the immunomodulatory secretome of #BoneMarrow mesenchymal stromal cells, and may influence the immune environment of the bone marrow niche. Read the study: go.nature.com/4usH2nQ

I just found out that Bayer's stem-cell derived Parkinson's therapy, which aims to replenish dopamine-producing neurons, is already in phase 3 testing – with the first patients treated Results are expected next year (yes, the trial is sham surgery-controlled!)

This new #review from the lab of Dr. Mohamed Mahameed at @HebrewU explores bioengineering strategies to improve CAR-T cell performance in #SolidTumors by enhancing tumor targeting, persistence, and resistance to the suppressive tumor microenvironment. 📖 Read more in @TrendsinBiotech: bit.ly/4wHb88D

Automation and AI are reshaping organoid research. 🚨 Scientists discuss how combining iPSC-derived organoids with automation is poised to transform disease modeling and drug development. Learn more here: bit.ly/43kozO9